MRI as an outcome in multiple sclerosis clinical trials
- 24 February 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 72 (8) , 705-711
- https://doi.org/10.1212/01.wnl.0000336916.38629.43
Abstract
Introduction: T2-weighted and gadolinium enhanced T1-weighted MRI scans measure plaque burden and breakdown of the blood-brain barrier, respectively, in multiple sclerosis (MS) lesions. These have become widely used outcome measures for monitoring disease activity in clinical trials and clinical practice. However, their use as surrogates or biomarkers for disability and relapses, key clinical outcome measures, has remained incompletely validated.Keywords
This publication has 28 references indexed in Scilit:
- Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosisBrain, 2006
- The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the diseaseBrain, 2006
- Cortical demyelination and diffuse white matter injury in multiple sclerosisBrain, 2005
- Reply to ‘Time-resolved sex differences in language lateralization’Brain, 2005
- Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pensionMultiple Sclerosis Journal, 2001
- MRI: measure of efficacyBrain, 2000
- The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-upBrain, 1998
- THE PATHOPHYSIOLOGY OF ACUTE OPTIC NEURITISBrain, 1991
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- NUCLEAR MAGNETIC RESONANCE IMAGING OF THE BRAIN IN MULTIPLE SCLEROSISThe Lancet, 1981